The Retinoic Acid Receptor RXR Alpha pipeline drugs market research report outlays comprehensive information on the Retinoic Acid Receptor RXR Alpha targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Retinoic Acid Receptor RXR Alpha pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Dermatology, Central Nervous System, and Genetic Disorders which include the indications Colorectal Cancer, Pancreatic Cancer, Acne Vulgaris, Hand Dermatitis, Alzheimer’s Disease, Multiple Sclerosis, Genetic Disorders, and Tay-Sachs Disease. It also reviews key players involved in Retinoic Acid Receptor RXR Alpha targeted therapeutics development with respective active and dormant or discontinued products.
The Retinoic Acid Receptor RXR Alpha pipeline targets constitutes close to ten molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 1, 1, 1, 2, 1, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Retinoic Acid Receptor RXR Alpha overview
Retinoic acid receptor RXR alpha (RXRA) is a member of the retinoic acid receptor (RAR) subfamily of nuclear receptors. It is one of the three subtypes of retinoid X receptors (RXRs), which also includes RXRB and RXRG. RXRs are critical in mediating the effects of retinoids, which are a class of compounds related to vitamin A, and they play a significant role in regulating gene expression and various physiological processes.
For a complete picture of Retinoic Acid Receptor RXR Alpha’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
